世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

フランスの超音波不妊診断・治療市場:ケア経路別(不妊診断、機能、治療モニタリング)、エンドユーザー別(不妊科のある公立病院、民間不妊クリニック、外来センター)。機会分析および産業予測、2021-2030年


France Ultrasound Infertility Diagnosis and Treatment Market by Care Pathway (Infertility Diagnostics, Punction, and Treatment Monitoring) and End User (Public Hospital with Infertility Department, Private Fertility Clinics and Ambulatory Centers): Opportunity Analysis and Industry Forecast, 2021–2030

フランスの超音波不妊診断・治療市場は、2020年に3億3,654万ドル、2021年から2030年にかけて年率4.4%で成長し、2030年には5億2,236万ドルに達すると予測されています。 個人の不妊症は、男性または女性の生殖器... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Allied Market Research
アライドマーケットリサーチ
2022年1月13日 US$6,168
シングルユーザーライセンス
ライセンス・価格情報・注文方法はこちら
141 英語

 

サマリー

フランスの超音波不妊診断・治療市場は、2020年に3億3,654万ドル、2021年から2030年にかけて年率4.4%で成長し、2030年には5億2,236万ドルに達すると予測されています。
個人の不妊症は、男性または女性の生殖器系が自然妊娠できない状態と定義されています。超音波ガイド下不妊症診断とは、超音波を用いて男性および女性の不妊症の原因を特定する技術である。女性の場合、卵管閉塞、性感染症(STI)、子宮内膜症、子宮隔壁、子宮筋腫などの子宮疾患、多嚢胞性卵巣症候群(PCOS)などの卵巣疾患が主な不妊の原因です。一方、男性では、生殖管の閉塞、精巣障害、ホルモンバランスの乱れなどが不妊の原因となることがあります。
不妊治療サービスは、男性および女性の不妊症の治療に役立ちます。不妊治療には、体外受精(IVF)、不妊検査、子宮内人工授精、卵子凍結・胚バンクなどの方法があります。これらの治療法は、シングルマザー、LGBTQコミュニティ、子作りが困難なカップルによく選ばれています。子宮卵管造影、子宮卵管造影、子宮卵管フォーム超音波法など、超音波ガイド下で行う不妊診断では、女性の子宮に膣からの出血、流産の再発、子宮筋腫、ポリープ、瘢痕組織、その他の異常など、さまざまな問題がないかどうか判断するために使用されます。

子宮卵管造影は、卵管閉塞の判定に使用します。超音波ガイド下経膣針吸引/生検、精巣コアニードル生検(女性・男性)は、低侵襲な不妊症診断の手法として知られています。排卵モニタリングなどの治療モニタリングサービスは、キットで妊娠のための排卵を予測するための主要な技術の1つであり、安価であることが特徴です。
超音波不妊診断・治療市場の成長を牽引する主な要因としては、不妊症の増加、妊娠の遅れ、初産婦年齢の上昇、体外受精(IVF)の認知度向上、不妊診断の技術的進化などが挙げられます。世界銀行の出生率によると、2018年のフランスの合計(女性一人当たりの出生数)は1.88で、2019年には1.87に減少しています。不妊症は、世界中で何百万人もの生殖年齢にある人々に影響を与え、その家族や地域社会に影響を及ぼしています。世界中で何百万人もの生殖年齢にある人々が不妊の影響を受けており、その家族や地域社会に影響を与えています。したがって、不妊率の上昇と出生率の低下が市場成長の原動力になると予想されます。
また、座りがちなライフスタイルの採用の急増、アルコール、喫煙、タバコの消費量の増加、過度のストレス、不健康なライフスタイル、肥満患者の急増などが、超音波ガイド下不妊診断・治療モニタリングサービス市場の成長を促進すると予想されます。例えば、2019年、世界保健機関(WHO)の「タバコ使用の普及動向 2000-2025」に関する世界報告書によると、フランスの15歳以上の人々全体のタバコ使用率は、男性36.0、男性33.2と推定されました。
タバコの喫煙率は、男性33.0、女性30.0、2018年は約30.9と推計されました。したがって、このような高いタバコ消費量と喫煙は、男性および女性の出生率に影響を与え、それがフランスでの市場成長の原動力となることが予想されます。
さらに、OECD(経済協力開発機構)によると、フランスでは約10人に1人が肥満であり、40%近くが過体重(肥満を含む)であることが分かっています。OECDは、太りすぎの割合が10年以内にさらに10%増加すると推定している。また、2019年のEurostatによると、フランス女性の約40%が太り過ぎで、このうち約17%が肥満であるとのことです。,.月経障害や無排卵は、太り過ぎの女性に多くみられます。太りすぎや肥満の女性は、流産するリスクが高い。これらの女性は、受胎、流産、妊娠の問題だけでなく、子宮下垂や不妊症のリスクも高い。したがって、これらの要因はすべて、フランスの超音波不妊診断・治療市場の成長に大きく寄与しています。
さらに、体外受精の技術や凍結胚移植などの技術的な進歩が市場の成長を後押ししています。例えば、2021年6月、フランスの下院は、独身女性とレズビアンが初めて医学的生殖補助医療を利用できるようにする法律を承認しました。このように、人工授精や体外受精などの不妊治療へのアクセスの提供は、フランスにおける市場の成長を強化することが期待されます。
しかし、不妊診断にかかる費用、体外受精後のリスク、生殖補助医療にかかる費用の高さが市場成長の妨げになっています。一方、不妊治療分野の技術開発に対する政府の取り組みや、消費者の可処分所得水準の向上は、市場成長のための有益な機会を提供すると期待されています。
また、医療現場における処置の効率化やスムーズな出産を目的とした先端技術への需要の高まりは、予測期間中に市場成長のための新たな道を開くと期待されています。
フランスの超音波不妊診断・治療市場は、ケアパスウェイとエンドユーザーに区分されます。ケアパスウェイでは、不妊症診断、不妊症治療、治療モニタリングに区分され、ケアパスウェイでは、不妊症診断、不妊症治療、治療モニタリングに区分されます。不妊症診断分野は、さらに子宮ソノグラフィー、子宮卵管造影、子宮卵管発泡超音波法(HyFoSy)に分類されます。穿刺部門は、超音波ガイド下経膣針吸引/生検と超音波ガイド下コアニードル精巣生検に細分化されています。さらに、治療モニタリング分野は、凍結胚移植サービスと排卵モニタリングで構成されています。
エンドユーザーによって、市場は不妊治療部門を持つ公立病院、私立不妊治療クリニック、外来センターに分別されます。各エンドユーザーはさらに、不妊症診断、不妊症治療、治療モニタリングのケアパス経路に分類されます。
本レポートで紹介する主要企業は、パリのアメリカンホスピタル、アンプ・センター・サン・ロック、アンプ・ナテシア・リヨン、センター・チルギカル(ピエール・シェルストクリニック)、ファーティリティセンター・パルシ・イースト、ホスピタル・コチャン、病院グループ ディアコネス・クロワ・サンシモン、マテルニテ・デ・スブルーツ - ホスピタル ピエール ルケ、ポイントジン プレジャー、ラムジー ヘルスケア リミテッド(クリニック デ ラ ミューエット)等です。


ステークホルダーにとっての主なメリット
- 本レポートでは、フランスの超音波不妊診断・治療市場における現在および新興の市場動向とダイナミクスを幅広く分析し、有力なビジネスチャンスを明らかにします。
- 本調査では、国全体の競争環境を予測するために、市場の競争環境を提示します。
- 市場の成長を促進、制限する要因の包括的な分析を行っています。

主要な市場セグメント
#ケアパス別
##不妊症診断薬
###子宮ソノグラフィー
###子宮卵管造影法
###子宮卵管造影法(HyFoSy)
##機能
###超音波ガイド下経膣針吸引/生検
###超音波ガイド下コアニードル精巣生検
##治療モニタリング
###凍結胚移植
###排卵モニタリング

#エンドユーザー別
##不妊症科のある公立病院
###不妊症診断薬
###機能
###治療モニタリング
##私立不妊治療クリニック
###不妊症診断
###機能
###治療モニタリング
#外来診療センター
###不妊症診断
###機能
###治療モニタリング



#主要な市場関係者
##パリ・アメリカン病院
##Amp Center St Roch
##Amp Natecia Lyon
センター・チルギカル(ピエール・シェレスト・クリニック)##Centre Chirugical
##不妊治療センター・パルシイースト
##ホスピタル・コーチン
##♪病院グループ ディアコネス クロワ サン シモン
##ブルエ産院-ピエール・ルケス病院
##ポイントジン-プレジャー
##ラムゼイ・ヘルスケア・リミテッド(クリニーク・ドゥ・ラ・ミュエット)



ページTOPに戻る


目次

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profile in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Porter’s five forces analysis
3.3.Top player positioning, 2020
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increase in infertility rate
3.4.1.2.Delayed pregnancies
3.4.1.3.Technological advancements in ultrasound-guided infertility diagnosis
3.4.1.4.Increase in disposable income and rise in awareness regarding infertility treatment

3.4.2.Restraint

3.4.2.1.High cost for infertility diagnosis and treatment

3.4.3.Opportunity

3.4.3.1.Rise in trend of fertility tourism

3.4.4.Impact analysis

3.5.Impact analysis of COVID-19 on the market
3.6.Company profiles of ultrasound providers in infertility diagnosis and treatment market

3.6.1.CANON INC. (CANON MEDICAL SYSTEMS CORPORATION)

3.6.1.1.Company overview
3.6.1.2.Company snapshot
3.6.1.3.Operating business segments
3.6.1.4.Product portfolio
3.6.1.5.Business performance

3.6.2.GENERAL ELECTRIC COMPANY (GE HEALTHCARE)

3.6.2.1.Company overview
3.6.2.2.Company snapshot
3.6.2.3.Operating business segments
3.6.2.4.Product portfolio
3.6.2.5.Business performance
3.6.2.6.Key strategic moves and developments

3.6.3.KONINKLIJKE PHILIPS N.V

3.6.3.1.Company overview
3.6.3.2.Company snapshot
3.6.3.3.Operating business segments
3.6.3.4.Product portfolio
3.6.3.5.Business performance
3.6.3.6.Key strategic moves and developments

3.6.4.MINDRAY MEDICAL INTERNATIONAL LIMITED

3.6.4.1.Company overview
3.6.4.2.Company snapshot
3.6.4.3.Operating business segments
3.6.4.4.Product portfolio

3.6.5.SIEMENS AG

3.6.5.1.Company overview
3.6.5.2.Company snapshot
3.6.5.3.Operating business segments
3.6.5.4.Product portfolio
3.6.5.5.Business performance
3.6.5.6.Key strategic moves and developments

CHAPTER 4:FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY CARE PATHWAY

4.1.Overview

4.1.1.Market size and forecast

4.2.Infertility diagnostics

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type

4.2.2.1.Hysterosonography

4.2.2.1.1.Market size and forecast

4.2.2.2.Hysterosonosalpyngography

4.2.2.2.1.Market size and forecast

4.2.2.3.Hysterosalpingo-foam sonography (HyFoSy)

4.2.2.3.1.Market size and forecast

4.3.Punction

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type

4.3.2.1.Ultrasound-guided trans-vaginal needle aspiration/biopsy

4.3.2.1.1.Market size and forecast

4.3.2.2.Ultrasound-guided core-needle testicular biopsy

4.3.2.2.1.Market size and forecast

4.4.Treatment monitoring

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type

4.4.2.1.Frozen embryo transfer

4.4.2.1.1.Market size and forecast

4.4.2.2.Ovulation monitoring

4.4.2.2.1.Market size and forecast

CHAPTER 5:FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY END USER

5.1.Overview

5.1.1.Market size and forecast

5.2.Public hospital with infertility department

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by care pathway

5.2.2.1.Infertility diagnostics

5.2.2.1.1.Market size and forecast

5.2.2.2.Punction

5.2.2.2.1.Market size and forecast

5.2.2.3.Treatment monitoring

5.2.2.3.1.Market size and forecast

5.3.Private fertility clinics

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by care pathway

5.3.2.1.Infertility diagnostics

5.3.2.1.1.Market size and forecast

5.3.2.2.Punction

5.3.2.2.1.Market size and forecast

5.3.2.3.Treatment monitoring

5.3.2.3.1.Market size and forecast

5.4.Ambulatory centers

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by care pathway

5.4.2.1.Infertility diagnostics

5.4.2.1.1.Market size and forecast

5.4.2.2.Punction

5.4.2.2.1.Market size and forecast

5.4.2.3.Treatment monitoring

5.4.2.3.1.Market size and forecast

CHAPTER 6:COMPANY PROFILES

6.1.AMERICAN HOSPITAL 0F PARIS

6.1.1.Company overview
6.1.2.Company snapshot
6.1.3.Operating business segments
6.1.4.Product portfolio

6.2.AMP CENTER ST ROCH

6.2.1.Company overview
6.2.2.Company snapshot
6.2.3.Operating business segments
6.2.4.Product portfolio

6.3.AMP NATECIA LYON

6.3.1.Company overview
6.3.2.Company snapshot
6.3.3.Operating business segments
6.3.4.Product portfolio

6.4.CENTRE CHIRUGICAL (PIERRE CHEREST CLINIC)

6.4.1.Company overview
6.4.2.Company snapshot
6.4.3.Operating business segments
6.4.4.Product portfolio

6.5.FERTILITY CENTER-PARSI EAST

6.5.1.Company overview
6.5.2.Company snapshot
6.5.3.Operating business segments
6.5.4.Product portfolio

6.6.HOSPITAL COCHIN

6.6.1.Company overview
6.6.2.Company snapshot
6.6.3.Operating business segments
6.6.4.Product portfolio

6.7.HOSPITAL GROUP DIACONESSES CROIX SAINT-SIMON

6.7.1.Company overview
6.7.2.Company snapshot
6.7.3.Operating business segments
6.7.4.Product portfolio

6.8.MATERNITÉ DES BLUETS - HOSPITAL PIERRE ROUQUÈS

6.8.1.Company overview
6.8.2.Company snapshot
6.8.3.Operating business segment
6.8.4.Product portfolio

6.9.POINTGYN - PLEASURE

6.9.1.Company overview
6.9.2.Company snapshot
6.9.3.Operating business segments
6.9.4.Product portfolio

6.10.RAMSAY HEALTHCARE LIMITED (CLINIQUE DE LA MUETTE)

6.10.1.Company overview
6.10.2.Company snapshot
6.10.3.Operating business segments
6.10.4.Product portfolio
6.10.5.Business performance


List of Tables

LIST OF TABLES

TABLE 01.CANON: COMPANY SNAPSHOT
TABLE 02.CANON: OPERATING SEGMENTS
TABLE 03.CANON: PRODUCT PORTFOLIO
TABLE 04.GE: COMPANY SNAPSHOT
TABLE 05.GE: PRODUCT SEGMENTS
TABLE 06.GE: PRODUCT PORTFOLIO
TABLE 07.GE: KEY DEVELOPMENTS
TABLE 08.PHILIPS: COMPANY SNAPSHOT
TABLE 09.PHILIPS: PRODUCT SEGMENTS
TABLE 10.PHILIPS: PRODUCT PORTFOLIO
TABLE 11.PHILIPS: KEY DEVELOPMENTS
TABLE 12.MINDRAY: COMPANY SNAPSHOT
TABLE 13.MINDRAY: OPERATING SEGMENTS
TABLE 14.MINDRAY: PRODUCT PORTFOLIO
TABLE 15.SIEMENS: COMPANY SNAPSHOT
TABLE 16.SIEMENS: OPERATING BUSINESS SEGMENTS
TABLE 17.SIEMENS: PRODUCT PORTFOLIO
TABLE 18.SIEMENS: KEY DEVELOPMENTS
TABLE 19.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY CARE PATHWAY, 2020–2030 ($MILLION)
TABLE 20.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, BY TYPE, 2020–2030 ($MILLION)
TABLE 21.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, BY TYPE, 2020–2030($MILLION)
TABLE 22.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, BY TYPE, 2020–2030 ($MILLION)
TABLE 23.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 24.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUBLIC HOSPITAL WITH INFERTILITY DEPARTMENT, BY CARE PATHWAY, 2020–2030 ($MILLION)
TABLE 25.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PRIVATE FERTILITY CLINICS, BY CARE PATHWAY 2020–2030 ($MILLION)
TABLE 26.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR AMBULATORY CENTERS, BY CARE PATHWAY 2020–2030 ($MILLION)
TABLE 27.AMERICAN HOSPITAL: COMPANY SNAPSHOT
TABLE 28.AMERICAN HOSPITAL: OPERATING SEGMENT
TABLE 29.AMERICAN HOSPITAL: PRODUCT PORTFOLIO
TABLE 30.ST ROCH: COMPANY SNAPSHOT
TABLE 31.ST ROCH: OPERATING SEGMENTS
TABLE 32.ST ROCH: PRODUCT PORTFOLIO
TABLE 33.NATECIA: COMPANY SNAPSHOT
TABLE 34.NATECIA: OPERATING SEGMENTS
TABLE 35.NATECIA: PRODUCT PORTFOLIO
TABLE 36.CHIRUGICAL: COMPANY SNAPSHOT
TABLE 37.CHIRUGICAL: OPERATING SEGMENT
TABLE 38.CENTRE CHIRUGICAL: PRODUCT PORTFOLIO
TABLE 39.FERTILITY CENTER: COMPANY SNAPSHOT
TABLE 40.FERTILITY CENTER: OPERATING SEGMENT
TABLE 41.FERTILITY CENTER: PRODUCT PORTFOLIO
TABLE 42.COCHIN: COMPANY SNAPSHOT
TABLE 43.COCHIN: OPERATING SEGMENTS
TABLE 44.COCHIN: PRODUCT PORTFOLIO
TABLE 45.DIACONESSES: COMPANY SNAPSHOT
TABLE 46.DIACONESSES: OPERATING SEGMENT
TABLE 47.DIACONESSES: PRODUCT PORTFOLIO
TABLE 48.BLUETS: COMPANY SNAPSHOT
TABLE 49.BLUETS: OPERATING SEGMENTS
TABLE 50.BLUETS: PRODUCT PORTFOLIO
TABLE 51.POINTGYN: COMPANY SNAPSHOT
TABLE 52.POINTGYN: OPERATING SEGMENT
TABLE 53.POINTGYN: PRODUCT PORTFOLIO
TABLE 54.RAMSAY: COMPANY SNAPSHOT
TABLE 55.RAMSAY: OPERATING SEGMENTS
TABLE 56.RAMSAY: PRODUCT PORTFOLIO


List of Figures

LIST OF FIGURES

FIGURE 01.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET SEGMENTATION
FIGURE 02.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 03.MODERATE BARGAINING POWER OF BUYERS
FIGURE 04.MODERATE THREAT OF SUBSTITUTES
FIGURE 05.HIGH THREAT OF NEW ENTRANTS
FIGURE 06.MODERATE INTENSITY OF RIVALRY
FIGURE 07.TOP PLAYER POSITIONING, 2020
FIGURE 08.IMPACT ANALYSIS
FIGURE 09.CANON: NET SALES, 2018–2020 ($MILLION)
FIGURE 10.CANON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 11.CANON: REVENUE SHARE BY REGION, 2020(%)
FIGURE 12.GE: NET SALES, 2018–2020 ($MILLION)
FIGURE 13.GE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 14.GE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 15.PHILIPS: NET SALES, 2018–2020 ($MILLION)
FIGURE 16.PHILIPS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 17.PHILIPS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 18.SIEMENS: NET SALES, 2018–2020 ($MILLION)
FIGURE 19.SIEMENS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20.SIEMENS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 21.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR HYSTEROSONOGRAPHY, 2020–2030 ($MILLION)
FIGURE 22.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR HYSTEROSONOSALPYNGOGRAPHY , 2020–2030 ($MILLION)
FIGURE 23.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR HYFOSY, 2020–2030 ($MILLION)
FIGURE 24.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR ULTRASOUND GUIDED TRANS-VAGINAL NEEDLE ASPIRATION/BIOPSY, 2020–2030 ($MILLION)
FIGURE 25.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR ULTRASOUND GUIDED CORE-NEEDLE TESTICULAR BIOPSY, 2020–2030 ($MILLION)
FIGURE 26.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR FROZEN EMBRYO TRANSFER, 2020–2030 ($MILLION)
FIGURE 27.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR OVULATION MONITORING, 2020–2030 ($MILLION)
FIGURE 28.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, 2020–2030 ($MILLION)
FIGURE 29.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, 2020–2030 ($MILLION)
FIGURE 30.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, 2020–2030 ($MILLION)
FIGURE 31.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, 2020–2030 ($MILLION)
FIGURE 32.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, 2020–2030 ($MILLION)
FIGURE 33.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, 2020–2030 ($MILLION)
FIGURE 34.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, 2020–2030 ($MILLION)
FIGURE 35.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, 2020–2030 ($MILLION)
FIGURE 36.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, 2020–2030 ($MILLION)
FIGURE 37.RAMSAY: NET SALES, 2019–2021 ($MILLION)
FIGURE 38.RAMSAY: REVENUE SHARE, BY SEGMENT, 2021 (%)

 

ページTOPに戻る


 

Summary

The France ultrasound infertility diagnosis and treatment market was valued at $336.54 million in 2020, and is estimated to reach $522.36 million by 2030, growing at a CAGR of 4.4% from 2021 to 2030.
Infertility in individuals is defined as the inability of the male or female reproductive system to conceive naturally. Ultrasound-guided infertility diagnosis is a technique in which ultrasound waves are used for determination for the cause of infertility in males as well as females. In females, infertility is caused majorly due to blocked fallopian tubes; sexually transmitted infections (STIs); uterine disorders such as endometriosis, septate uterus, and fibroids; and ovarian disorder such as the polycystic ovarian syndrome (PCOS). On the contrary, in males, obstruction of the reproductive tract, testicular impairment, and hormonal misbalance may result in infertility.
Fertility services help treat infertility in men and women. The different forms of fertility treatments available include in vitro fertilization (IVF), fertility testing, intrauterine insemination, and egg freezing & embryo banking. These treatments are often opted by single mothers, the LGBTQ community, and couples who find it hard to procreate. Ultrasound-guided procedures for infertility diagnosis such as hysterosonography, hysterosonosalpyngography, and hysterosalpingo-foam sonography are used to determine the woman's uterus for a variety of issues such as vaginal bleeding, recurrent miscarriages, fibroids, polyps, scar tissue, or other abnormalities.

Hysterosonosalpyngography is used to determine the fallopian tubes blockage. Ultrasound-guided trans-vaginal needle aspiration/biopsy and core-needle testicular biopsy in females and males are the minimally invasive techniques that assess infertility diagnosis. Treatment monitoring service such as the ovulation monitoring is one of the majorly used techniques for predicting the ovulation for conceiving through kits and is less expensive.
The major factors that drive the growth of the ultrasound infertility diagnosis & treatment market include increase in prevalence of infertility rates, rise in trend of delayed pregnancies, surge in the number of median age of first-time mothers, increase in awareness of in vitro fertilization (IVF), and technological advancements for infertility diagnosis. According to the World Bank fertility rate, total (births per woman) in France in 2018 was 1.88, and it reduced to 1.87 in 2019. Infertility affects millions of people of reproductive age worldwide and has an impact on their families and communities. Millions of people of reproductive age around the world are affected by infertility, which has an impact on their families and communities. Thus, increase in infertility rates and reduction of birth rates is expected to drive the market growth.
In addition, surge in adoption of sedentary lifestyle; rise in alcohol, smoking, & tobacco consumption; excessive stress; unhealthy lifestyle; and surge in obesity cases are expected to drive the growth of the ultrasound-guided infertility diagnosis & treatment monitoring services market. For instance, in 2019, according to the World Health Organization (WHO) global report on trends in prevalence of tobacco use 2000–2025, the tobacco use rates across the people in France aged 15 years and older, was estimated to be 36.0 in males and 33.2 in males.
Cigarette smoking rates were estimated to be 33.0 in males and 30.0 in females and about 30.9 in 2018. Thus, such high tobacco consumption and smoking is expected to affect the fertility of males and females, which, in turn, drives the growth of the market in France.
Moreover, according to the Organisation for Economic Co-operation and Development (OECD), about 1 in 10 individuals is obese in France, and almost 40% are overweight (including obese). OECD has estimated that overweight rates will increase by a further 10% within 10 years. In addition, according to the Eurostat in 2019, about 40% of French women were overweight, and among this, about 17% of women were obese. ,. Menstrual disorders and anovulation are more common in overweight women. Women who are overweight or obese are at a higher risk of having a miscarriage. These women have a higher risk of subfecundity and infertility as well as conception, miscarriage, and pregnancy problems. Thus, all these factors notably contribute toward the growth of the France ultrasound infertility diagnosis and treatment market.
Furthermore, technological advancements IVF techniques and frozen embryo transfer boost the market growth. For instance, in June 2021, France’s Lower House of Parliament approved a law that will allow single women and lesbians to access medically assisted reproduction for the first time. Thus, provision of access to fertility treatments such as artificial insemination and IVF is expected to strengthen the growth of the market in France.
However, high cost of infertility diagnosis procedures, risk associated after IVF procedure, and high cost of assisted reproductive technology hinder the market growth. On the contrary, initiatives taken by governments for development of the technology sector in infertility and increase in disposable income level of consumers are expected to offer remunerative opportunities for the market growth.
In addition, surge in demand for advanced technologies in healthcare to enhance efficiency of procedures and smooth delivery of babies is expected to open new avenues for the market growth during the forecast period.
The France ultrasound infertility diagnosis and treatment market is segmented into care pathway and end user. On the basis of care pathway, the market is fragmented into infertility diagnostics, punction, and treatment monitoring. The infertility diagnostics segment is further classified into hysterosonography, hysterosonosalpyngography, and hysterosalpingo-foam sonography (HyFoSy). The punction segment is subsegmented into ultrasound-guided trans-vaginal needle aspiration/biopsy and ultrasound guided core-needle testicular biopsy. Moreover, the treatment monitoring segment comprises frozen embryo transfer services and ovulation monitoring.
Depending on end user, the market is segregated into public hospital with infertility department, private fertility clinics and ambulatory centers. Each end user is further segmented into the care pathway bifurcation of infertility diagnostics, punction, and treatment monitoring.
The major players profiled in the report are American Hospital of Paris, Amp Center St Roch, Amp Natecia Lyon, Centre Chirugical (Pierre Cherest Clinic), Fertility Center-Parsi East, Hospital Cochin, Hospital Group Diaconesses Croix Saint-Simon, Maternité Des Bluets - Hospital Pierre Rouquès, Pointgyn-Pleasure and Ramsay Healthcare Limited (Clinique De La Muette).


KEY BENEFITS FOR STAKEHOLDERS
• This report provides an extensive analysis of the current and emerging market trends and dynamics in the France ultrasound infertility diagnosis and treatment market to identify the prevailing opportunities.
• This study presents the competitive landscape of the market to predict the competitive environment across the country.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.

KEY MARKET SEGMENTS
#By Care Pathways
##Infertility Diagnostics
###Hysterosonography
###Hysterosonosalpyngography
###Hysterosalpingo-foam Sonography (HyFoSy)
##Punction
###Ultrasound-guided trans-vaginal Needle Aspiration/Biopsy
###Ultrasound-guided core-needle Testicular Biopsy
##Treatment Monitoring
###Frozen Embryo Transfer
###Ovulation Monitoring

#By End User
##Public Hospital with Infertility Department
###Infertility Diagnostics
###Punction
###Treatment Monitoring
##Private Fertility Clinics
###Infertility diagnostics
###Punction
###Treatment Monitoring
##Ambulatory Centers
###Infertility Diagnostics
###Punction
###Treatment Monitoring



#KEY MARKET PLAYERS
##American Hospital of Paris
##Amp Center St Roch
##Amp Natecia Lyon
##Centre Chirugical (Pierre Cherest Clinic)
##Fertility Center-Parsi East
##Hospital Cochin
##Hospital Group Diaconesses Croix Saint-Simon
##Maternité Des Bluets - Hospital Pierre Rouquès
##Pointgyn-Pleasure
##Ramsay Healthcare Limited (Clinique De La Muette)



ページTOPに戻る


Table of Contents

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profile in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Porter’s five forces analysis
3.3.Top player positioning, 2020
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increase in infertility rate
3.4.1.2.Delayed pregnancies
3.4.1.3.Technological advancements in ultrasound-guided infertility diagnosis
3.4.1.4.Increase in disposable income and rise in awareness regarding infertility treatment

3.4.2.Restraint

3.4.2.1.High cost for infertility diagnosis and treatment

3.4.3.Opportunity

3.4.3.1.Rise in trend of fertility tourism

3.4.4.Impact analysis

3.5.Impact analysis of COVID-19 on the market
3.6.Company profiles of ultrasound providers in infertility diagnosis and treatment market

3.6.1.CANON INC. (CANON MEDICAL SYSTEMS CORPORATION)

3.6.1.1.Company overview
3.6.1.2.Company snapshot
3.6.1.3.Operating business segments
3.6.1.4.Product portfolio
3.6.1.5.Business performance

3.6.2.GENERAL ELECTRIC COMPANY (GE HEALTHCARE)

3.6.2.1.Company overview
3.6.2.2.Company snapshot
3.6.2.3.Operating business segments
3.6.2.4.Product portfolio
3.6.2.5.Business performance
3.6.2.6.Key strategic moves and developments

3.6.3.KONINKLIJKE PHILIPS N.V

3.6.3.1.Company overview
3.6.3.2.Company snapshot
3.6.3.3.Operating business segments
3.6.3.4.Product portfolio
3.6.3.5.Business performance
3.6.3.6.Key strategic moves and developments

3.6.4.MINDRAY MEDICAL INTERNATIONAL LIMITED

3.6.4.1.Company overview
3.6.4.2.Company snapshot
3.6.4.3.Operating business segments
3.6.4.4.Product portfolio

3.6.5.SIEMENS AG

3.6.5.1.Company overview
3.6.5.2.Company snapshot
3.6.5.3.Operating business segments
3.6.5.4.Product portfolio
3.6.5.5.Business performance
3.6.5.6.Key strategic moves and developments

CHAPTER 4:FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY CARE PATHWAY

4.1.Overview

4.1.1.Market size and forecast

4.2.Infertility diagnostics

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type

4.2.2.1.Hysterosonography

4.2.2.1.1.Market size and forecast

4.2.2.2.Hysterosonosalpyngography

4.2.2.2.1.Market size and forecast

4.2.2.3.Hysterosalpingo-foam sonography (HyFoSy)

4.2.2.3.1.Market size and forecast

4.3.Punction

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type

4.3.2.1.Ultrasound-guided trans-vaginal needle aspiration/biopsy

4.3.2.1.1.Market size and forecast

4.3.2.2.Ultrasound-guided core-needle testicular biopsy

4.3.2.2.1.Market size and forecast

4.4.Treatment monitoring

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type

4.4.2.1.Frozen embryo transfer

4.4.2.1.1.Market size and forecast

4.4.2.2.Ovulation monitoring

4.4.2.2.1.Market size and forecast

CHAPTER 5:FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY END USER

5.1.Overview

5.1.1.Market size and forecast

5.2.Public hospital with infertility department

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by care pathway

5.2.2.1.Infertility diagnostics

5.2.2.1.1.Market size and forecast

5.2.2.2.Punction

5.2.2.2.1.Market size and forecast

5.2.2.3.Treatment monitoring

5.2.2.3.1.Market size and forecast

5.3.Private fertility clinics

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by care pathway

5.3.2.1.Infertility diagnostics

5.3.2.1.1.Market size and forecast

5.3.2.2.Punction

5.3.2.2.1.Market size and forecast

5.3.2.3.Treatment monitoring

5.3.2.3.1.Market size and forecast

5.4.Ambulatory centers

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by care pathway

5.4.2.1.Infertility diagnostics

5.4.2.1.1.Market size and forecast

5.4.2.2.Punction

5.4.2.2.1.Market size and forecast

5.4.2.3.Treatment monitoring

5.4.2.3.1.Market size and forecast

CHAPTER 6:COMPANY PROFILES

6.1.AMERICAN HOSPITAL 0F PARIS

6.1.1.Company overview
6.1.2.Company snapshot
6.1.3.Operating business segments
6.1.4.Product portfolio

6.2.AMP CENTER ST ROCH

6.2.1.Company overview
6.2.2.Company snapshot
6.2.3.Operating business segments
6.2.4.Product portfolio

6.3.AMP NATECIA LYON

6.3.1.Company overview
6.3.2.Company snapshot
6.3.3.Operating business segments
6.3.4.Product portfolio

6.4.CENTRE CHIRUGICAL (PIERRE CHEREST CLINIC)

6.4.1.Company overview
6.4.2.Company snapshot
6.4.3.Operating business segments
6.4.4.Product portfolio

6.5.FERTILITY CENTER-PARSI EAST

6.5.1.Company overview
6.5.2.Company snapshot
6.5.3.Operating business segments
6.5.4.Product portfolio

6.6.HOSPITAL COCHIN

6.6.1.Company overview
6.6.2.Company snapshot
6.6.3.Operating business segments
6.6.4.Product portfolio

6.7.HOSPITAL GROUP DIACONESSES CROIX SAINT-SIMON

6.7.1.Company overview
6.7.2.Company snapshot
6.7.3.Operating business segments
6.7.4.Product portfolio

6.8.MATERNITÉ DES BLUETS - HOSPITAL PIERRE ROUQUÈS

6.8.1.Company overview
6.8.2.Company snapshot
6.8.3.Operating business segment
6.8.4.Product portfolio

6.9.POINTGYN - PLEASURE

6.9.1.Company overview
6.9.2.Company snapshot
6.9.3.Operating business segments
6.9.4.Product portfolio

6.10.RAMSAY HEALTHCARE LIMITED (CLINIQUE DE LA MUETTE)

6.10.1.Company overview
6.10.2.Company snapshot
6.10.3.Operating business segments
6.10.4.Product portfolio
6.10.5.Business performance


List of Tables

LIST OF TABLES

TABLE 01.CANON: COMPANY SNAPSHOT
TABLE 02.CANON: OPERATING SEGMENTS
TABLE 03.CANON: PRODUCT PORTFOLIO
TABLE 04.GE: COMPANY SNAPSHOT
TABLE 05.GE: PRODUCT SEGMENTS
TABLE 06.GE: PRODUCT PORTFOLIO
TABLE 07.GE: KEY DEVELOPMENTS
TABLE 08.PHILIPS: COMPANY SNAPSHOT
TABLE 09.PHILIPS: PRODUCT SEGMENTS
TABLE 10.PHILIPS: PRODUCT PORTFOLIO
TABLE 11.PHILIPS: KEY DEVELOPMENTS
TABLE 12.MINDRAY: COMPANY SNAPSHOT
TABLE 13.MINDRAY: OPERATING SEGMENTS
TABLE 14.MINDRAY: PRODUCT PORTFOLIO
TABLE 15.SIEMENS: COMPANY SNAPSHOT
TABLE 16.SIEMENS: OPERATING BUSINESS SEGMENTS
TABLE 17.SIEMENS: PRODUCT PORTFOLIO
TABLE 18.SIEMENS: KEY DEVELOPMENTS
TABLE 19.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY CARE PATHWAY, 2020–2030 ($MILLION)
TABLE 20.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, BY TYPE, 2020–2030 ($MILLION)
TABLE 21.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, BY TYPE, 2020–2030($MILLION)
TABLE 22.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, BY TYPE, 2020–2030 ($MILLION)
TABLE 23.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 24.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUBLIC HOSPITAL WITH INFERTILITY DEPARTMENT, BY CARE PATHWAY, 2020–2030 ($MILLION)
TABLE 25.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PRIVATE FERTILITY CLINICS, BY CARE PATHWAY 2020–2030 ($MILLION)
TABLE 26.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR AMBULATORY CENTERS, BY CARE PATHWAY 2020–2030 ($MILLION)
TABLE 27.AMERICAN HOSPITAL: COMPANY SNAPSHOT
TABLE 28.AMERICAN HOSPITAL: OPERATING SEGMENT
TABLE 29.AMERICAN HOSPITAL: PRODUCT PORTFOLIO
TABLE 30.ST ROCH: COMPANY SNAPSHOT
TABLE 31.ST ROCH: OPERATING SEGMENTS
TABLE 32.ST ROCH: PRODUCT PORTFOLIO
TABLE 33.NATECIA: COMPANY SNAPSHOT
TABLE 34.NATECIA: OPERATING SEGMENTS
TABLE 35.NATECIA: PRODUCT PORTFOLIO
TABLE 36.CHIRUGICAL: COMPANY SNAPSHOT
TABLE 37.CHIRUGICAL: OPERATING SEGMENT
TABLE 38.CENTRE CHIRUGICAL: PRODUCT PORTFOLIO
TABLE 39.FERTILITY CENTER: COMPANY SNAPSHOT
TABLE 40.FERTILITY CENTER: OPERATING SEGMENT
TABLE 41.FERTILITY CENTER: PRODUCT PORTFOLIO
TABLE 42.COCHIN: COMPANY SNAPSHOT
TABLE 43.COCHIN: OPERATING SEGMENTS
TABLE 44.COCHIN: PRODUCT PORTFOLIO
TABLE 45.DIACONESSES: COMPANY SNAPSHOT
TABLE 46.DIACONESSES: OPERATING SEGMENT
TABLE 47.DIACONESSES: PRODUCT PORTFOLIO
TABLE 48.BLUETS: COMPANY SNAPSHOT
TABLE 49.BLUETS: OPERATING SEGMENTS
TABLE 50.BLUETS: PRODUCT PORTFOLIO
TABLE 51.POINTGYN: COMPANY SNAPSHOT
TABLE 52.POINTGYN: OPERATING SEGMENT
TABLE 53.POINTGYN: PRODUCT PORTFOLIO
TABLE 54.RAMSAY: COMPANY SNAPSHOT
TABLE 55.RAMSAY: OPERATING SEGMENTS
TABLE 56.RAMSAY: PRODUCT PORTFOLIO


List of Figures

LIST OF FIGURES

FIGURE 01.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET SEGMENTATION
FIGURE 02.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 03.MODERATE BARGAINING POWER OF BUYERS
FIGURE 04.MODERATE THREAT OF SUBSTITUTES
FIGURE 05.HIGH THREAT OF NEW ENTRANTS
FIGURE 06.MODERATE INTENSITY OF RIVALRY
FIGURE 07.TOP PLAYER POSITIONING, 2020
FIGURE 08.IMPACT ANALYSIS
FIGURE 09.CANON: NET SALES, 2018–2020 ($MILLION)
FIGURE 10.CANON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 11.CANON: REVENUE SHARE BY REGION, 2020(%)
FIGURE 12.GE: NET SALES, 2018–2020 ($MILLION)
FIGURE 13.GE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 14.GE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 15.PHILIPS: NET SALES, 2018–2020 ($MILLION)
FIGURE 16.PHILIPS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 17.PHILIPS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 18.SIEMENS: NET SALES, 2018–2020 ($MILLION)
FIGURE 19.SIEMENS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20.SIEMENS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 21.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR HYSTEROSONOGRAPHY, 2020–2030 ($MILLION)
FIGURE 22.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR HYSTEROSONOSALPYNGOGRAPHY , 2020–2030 ($MILLION)
FIGURE 23.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR HYFOSY, 2020–2030 ($MILLION)
FIGURE 24.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR ULTRASOUND GUIDED TRANS-VAGINAL NEEDLE ASPIRATION/BIOPSY, 2020–2030 ($MILLION)
FIGURE 25.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR ULTRASOUND GUIDED CORE-NEEDLE TESTICULAR BIOPSY, 2020–2030 ($MILLION)
FIGURE 26.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR FROZEN EMBRYO TRANSFER, 2020–2030 ($MILLION)
FIGURE 27.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR OVULATION MONITORING, 2020–2030 ($MILLION)
FIGURE 28.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, 2020–2030 ($MILLION)
FIGURE 29.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, 2020–2030 ($MILLION)
FIGURE 30.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, 2020–2030 ($MILLION)
FIGURE 31.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, 2020–2030 ($MILLION)
FIGURE 32.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, 2020–2030 ($MILLION)
FIGURE 33.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, 2020–2030 ($MILLION)
FIGURE 34.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, 2020–2030 ($MILLION)
FIGURE 35.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, 2020–2030 ($MILLION)
FIGURE 36.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, 2020–2030 ($MILLION)
FIGURE 37.RAMSAY: NET SALES, 2019–2021 ($MILLION)
FIGURE 38.RAMSAY: REVENUE SHARE, BY SEGMENT, 2021 (%)

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(診断薬)の最新刊レポート

Allied Market Research 社の最新刊レポート

本レポートと同じKEY WORD(ambulatory)の最新刊レポート


よくあるご質問


Allied Market Research社はどのような調査会社ですか?


アライドマーケットリサーチ(Allied Market Research)は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/10/04 10:27

147.72 円

163.39 円

196.69 円

ページTOPに戻る